Login to Your Account



Arrowhead, Shire Ink Targeted Peptide-Drug Conjugate Deal

By Marie Powers
Staff Writer

Wednesday, December 19, 2012
Less than a year after the acquisition of Alvos Therapeutics Inc. gave Arrowhead Research Corp. a library of 42,000 individual targeting sequences, the company has attracted a second research collaboration and license deal.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription